Risk factors of relapse in pulmonary sarcoidosis treated with corticosteroids
To evaluate the incidence and risk factors of relapse in pulmonary sarcoidosis treated with corticosteroids.
Medical records of patients with pulmonary sarcoidosis were retrospectively reviewed. Clinical features, chest radiographs, pulmonary function tests, and treatment information were collected. The starting point was the date of diagnosis. Clinical relapse was defined as chest high-resolution computed tomography (HRCT) showing radiographic progression in combination of worsening of clinical symptoms to warrant retreatment following a decrease in dose or discontinuation of corticosteroids, without alternative causes such as infections, heart failure, or pulmonary embolism. Non-relapse was defined as remission of clinical symptoms and chest abnormalities, or clinical syndrome improvement with retention or stability of radiographic abnormalities after corticosteroids were withdrawn for at least 6 months. The primary endpoint was the occurrence of relapse.
Two hundred three patients with newly biopsy-proven pulmonary sarcoidosis were enrolled over a 7-year period. Among them, 96 patients received corticosteroids therapy. Relapse occurred in 30 patients with the relapse rate yielding 30/96 (31.25%). After adjustment, multivariate analysis showed that smoking history (HR = 3.674 95% CI 1.573–8.581, P = 0.003) and increased percentages of circulating neutrophils (> 70%) (HR = 2.211, 95% CI 1.073–4.557, P = 0.032) were the significant predictors of relapse in pulmonary sarcoidosis treated with corticosteroids.
This study provided useful information that the relapse and associated risk factors should be taken into considerations when determining treatment strategies for patients with pulmonary sarcoidosis.
KeywordsCorticosteroid Pulmonary sarcoidosis Relapse Risk factor
The study was supported by the National Natural Science Foundation of China (81570058), Jiangsu Provincial Medical Talent (ZDRCA2016058), and Jiangsu Social Development Project (BE2017604).
Compliance with ethical standards
The ethics approval was acquired according to the policy of the Ethics Committee of the Affiliated Drum Tower Hospital of Nanjing University Medical School.
- 6.Johns CJ, Schonfeld SA, Scott PP, Zachary JB, MacGregor MI (1986) Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci 465:702–712 https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=1986&volume=465&spage=702 CrossRefPubMedGoogle Scholar
- 8.Baughman RP, Shipley R, Desai S, Drent M, Judson MA, Costabel U, du Bois RM, Kavuru M, Schlenker-Herceg R, Flavin S, Lo KH, Barnathan ES (2009) Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest 136:526–535. https://doi.org/10.1378/chest.08-1876 CrossRefPubMedGoogle Scholar
- 9.(1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160: 736–55. https://doi.org/10.1164/ajrccm.160.2.ats4-99
- 10.Judson MA (1999) An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 115:1158–1165 https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(16)37755-8 CrossRefPubMedGoogle Scholar
- 14.Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Müller-Quernheim J (1998) Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med 46:223–231 https://www.ncbi.nlm.nih.gov/pubmed/9676055 PubMedGoogle Scholar
- 15.Drent M, Jacobs J, de Vries J, Lamers R, Liem I, Wouters E (1999) Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J 13:1338–1344 https://erj.ersjournals.com/content/erj/13/6/1338.full.pdf CrossRefPubMedGoogle Scholar
- 16.Ziegenhagen MW, Rothe ME, Schlaak M, Müller-Quernheim J (2003) Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J 21:407–413 https://erj.ersjournals.com/content/erj/21/3/407.full.pdf CrossRefPubMedGoogle Scholar
- 17.Matusiewicz SP, Williamson IJ, Sime PJ, Brown PH, Wenham PR, Crompton GK, Greening AP (1993) Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis? Eur Respir J 6:1282–1286 https://www.ncbi.nlm.nih.gov/pubmed/8287944 PubMedGoogle Scholar
- 18.Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chapelon-Abric C, Lyon-Caen O, Valeyre D, Piette JC (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89:133–140 https://www.ncbi.nlm.nih.gov/pubmed/20517184 CrossRefGoogle Scholar
- 20.Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H, Johns CJ, Rabin DL, Rybicki BA, Cherniack R (2004) A case control etiologic study of sarcoidosis. Am J Respir Crit Care Med 170:1324–1330. https://doi.org/10.1164/rccm.200402-249OC CrossRefPubMedGoogle Scholar
- 21.Wang SH, Chung CH, Huang TW, Tsai WC, Peng CK, Huang KL, Perng WC, Chian CF, Chien WC, Shen CH (2019) Bidirectional association between tuberculosis and sarcoidosis. Respirology. https://doi.org/10.1111/resp.13482
- 23.Baughman RP, Winget DB, Lower E (2000) Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17:60–66 https://www.ncbi.nlm.nih.gov/pubmed/?term=Methotrexate+is+steroid+sparing+in+acute+sarcoidosis%3A+results+of+a+double+blind%2C+randomized+trial PubMedGoogle Scholar
- 26.Hunninghake GW, Costabel U, Ando M, Baughman RP, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis 16:149–173 https://www.ncbi.nlm.nih.gov/pubmed/10560120 PubMedGoogle Scholar